You are here

revusiran

Alnylam review turns up no clear answers on revusiran deaths

BioPharma Dive

Thu, 08/10/17 - 06:53 pm

7 of the Most Shocking Biotech Pipeline Blowups of 2016

Motley Fool

Sun, 12/4/16 - 12:37 pm

Clovis Oncology

Celldex Therapeutics

Alnylam Pharma stock plummets 45% after discontinuing drug on patient safety concerns

Marketwatch

Thu, 10/6/16 - 09:24 am

clinical trials

Alnylam reports results from Phase 2 revusiran trial

Seeking Alpha

Fri, 11/14/14 - 09:54 am

TTR cardiac amyloidosis